Projects

Targeting novel sites on reverse transcriptase for HIV treatment and prevention

Our overall aim is to characterise new drug scaffolds and their novel binding sites on HIV reverse transcriptase to advance fundamental understanding of reverse transcriptase structure and function and to underpin the discovery of a new HIV drug class.

This new drug class is aimed to have a distinct mechanism of action and resistance profile to drugs currently used for HIV treatment and prevention

Timeline

2017 – 2019

Publications

2016

2015

Collaborators

Associate Professor David Chalmers Professor Nicolas Sluis-Cremer Professor Eddy Arnold Associate Professor Philip Thompson Dr Stephen Headey Dr Catherine Latham Dr Joseph Bauman Professor Martin Scanlon Professor Susan Charman

Funding

NHMRC

Health Issue

Contact Details

For any general enquiries relating to this project, please contact:

Professor Gilda Tachedjian

Head of Life Sciences; Head of Tachedjian Laboratory (Retroviral Biology and Antivirals)

Telephone

+61392822256

Email

[email protected]